Arcellx has been granted a patent for D domain polypeptides that bind specific targets, including CD123. The invention includes nucleic acids, vectors, and host cells for diagnostic and therapeutic applications. Additionally, multi-functional CAR-based compositions and Adapters are provided for directing immune responses to target cells. GlobalData’s report on Arcellx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arcellx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arcellx, Peptide pharmacophores was a key innovation area identified from patents. Arcellx's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for d domain polypeptide binding cd123

Source: United States Patent and Trademark Office (USPTO). Credit: Arcellx Inc

A recently granted patent (Publication Number: US11827716B2) discloses a range of claims related to a D Domain target binding polypeptide that specifically binds CD123. The patent covers various aspects, including a polypeptide fused to a heterologous polypeptide, labeled or conjugated to a therapeutic agent, isolated polynucleotides encoding the polypeptide, methods of production, pharmaceutical compositions, and chimeric antigen receptors (CARs) incorporating the D domain. The CARs further include transmembrane and intracellular signaling domains, with specific amino acid sequences provided in the claims. Additionally, the patent describes adapters for delivering an immune response to target cells, methods of killing target cells or treating cancer, and compositions for administering to patients.

Furthermore, the patent details methods of delivering an immune response to target cells, killing target cells, or treating cancer in patients by administering cells expressing the CAR or adapters comprising the D domain that binds to CD123 and an AFP p26 antigenic determinant. The claims encompass various scenarios involving the administration of cells expressing CARs with specific domains and sequences, as well as the use of adapters in conjunction with these cells. The methods outlined in the patent aim to provide targeted immune responses, particularly in the context of hematological cancers like acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome, utilizing the specified polypeptides, polynucleotides, and compositions described in the claims.

To know more about GlobalData’s detailed insights on Arcellx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies